Key result
Safe-dose thrombolysis plus rivaroxaban in patients with symptomatic pulmonary embolism reduced pulmonary artery systolic pressure from 52.8 to 32 mm Hg within 36 hours.
Why the study?
Does safe-dose thrombolysis plus rivaroxaban improve outcomes and reduce hospitalization time in patients with moderate and severe pulmonary embolism?
Cohort (n=98)
Does safe-dose thrombolysis plus rivaroxaban improve outcomes and reduce hospitalization time in patients with moderate and severe pulmonary embolism?
The combination of safe-dose thrombolysis and rivaroxaban appears safe and effective for moderate to severe pulmonary embolism, significantly reducing pulmonary artery pressures and facilitating early hospital discharge.
Answers are grounded in this paper and cite their sources.
May reduce PASP rapidly in symptomatic PE without bleeding; leaves open need for randomized confirmation before practice change.
BACKGROUND: Thrombolysis, though very effective, has not been embraced as routine therapy for symptomatic pulmonary embolism (PE) except in very severe cases. Rivaroxaban recently has been approved for the treatment of venous thromboembolism (VTE). There are no data on the combined use of thrombolysis and rivaroxaban in PE. HYPOTHESIS: "Safe dose" thrombolysis (SDT) plus new oral anticoagulants are expected to become an appealing, safe and effective approach in the treatment of moderate and severe PE in the near future, thereby drastically reducing hospitalization time. METHODS: Over a 12-month period, 98 consecutive patients with symptomatic PE were treated by a combination of SDT and rivaroxaban. The SDT was started in parallel with unfractionated heparin and given in 2 hours. Heparin was given for a total of 24 hours and rivaroxaban started at 15 or 20 mg daily 2 hours after termination of heparin infusion. RESULTS: There was no bleeding due to SDT. Recurrent VTE occurred in 3 patients who had been switched to warfarin. No patient on rivaroxaban developed VTE. Two patients died of cancer at a mean follow-up of 12 ± 2 months. The pulmonary artery systolic pressure dropped from 52.8 ± 3.9 mm Hg before to 32 ± 4.4 mm Hg within 36 hours of SDT (P < 0.001). The duration of hospitalization for patients presenting primarily for PE was 1.9 ± 0.2 days. CONCLUSIONS: "Safe dose" thrombolysis plus rivaroxaban is highly safe and effective in the treatment of moderate and severe PE, leading to favorable early and intermediate-term outcomes and early discharge.
No takes yet. Share an insight, caveat, or question.
Sharifi et al. (2013) conducted a cohort in symptomatic pulmonary embolism (n=98). Safe-dose thrombolysis plus rivaroxaban was evaluated on pulmonary artery systolic pressure (p=<0.001). Safe-dose thrombolysis plus rivaroxaban in patients with symptomatic pulmonary embolism reduced pulmonary artery systolic pressure from 52.8 to 32 mm Hg within 36 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: